| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05405192 Details | 2023-02-28 Interventional | 2 | 0 | Dostarlimab Gestational Tro… Neoplasms Gestational Tro… | PI is leaving the University. - | |||
| NCT03991299 Details | 2023-02-28 Interventional | 1/2 | 4 | Botulinum Toxin… Diabetes Mellit… Weight Loss Obese | Sponsor Decision. Early termination leading to small numbers of subjects enrolled. Technical problems due to limited enrollment leading to uninterpretable data. | |||
| NCT03251924 2017-000238-73 Details | 2023-02-28 Interventional | 1/2 | 80 | Antibodies Antibodies, Blo… Immunoglobulins Ipilimumab Nivolumab Neoplasms Cancer Malignancy Neoplasm Tumors | Study CA021-002 was terminated because the Sponsor discontinued further development of
BMS-986226 due to a change in business objectives. The decision for the study closure was not
related to any safety concerns associated with BMS-986226. Study CA021002 was terminated because the Sponsor discontinued further development of BMS-986226. The decision for the study closure was not related to any safety concerns associated with BMS-986226. | |||
| NCT05705700 Details | 2023-02-27 Interventional | 2 | 0 | Dutasteride Prostatic Neopl… Prostate Cancer | Feasibility - | |||
| NCT05622058 2022-000158-27 Details | 2023-02-27 Interventional | 1 | 6 | Cyclophosphamid… Docetaxel Doxorubicin Breast Neoplasm… Prevention of C… | The study has been terminated early given that the first four patients enrolled have
experienced Grade 4 neutropenia and alopecia after cycle 1 and as such failed to meet the
primary endpoint and the main secondary endpoint. - | |||
| NCT04557384 Details | 2023-02-27 Interventional | 1 | 3 | Ramucirumab Advanced Solid … | Study terminated due to inadequate PK profile associated with the subcutaneous formulation. Study was terminated due to low likelihood of achieving a relevant therapeutic exposure. | |||
| NCT03874234 Details | 2023-02-27 Interventional | 1 | 25 | GSK3186899 Leishmaniasis | The trial was terminated early following strategic review after emergence of nonclinical data
with a non-GlaxoSmithKline asset. - | |||
| NCT02292225 Details | 2023-02-27 Interventional | 1 | 3 | Obinutuzumab Leukemia, Lymph… Lymphocytic Leu… Lymphoma, Small… | The scope of the program has been reduced to focus resources on studies which can potentially
enable the registration of duvelisib. - | |||
| NCT05744115 Details | 2023-02-24 Interventional | 3 | 38 | Gallium 68 PSMA… Prostatic Neopl… Prostate Adenoc… Prostate Cancer | The investigational product was approved by the FDA (12/20/2021) and is now commercially
available - | |||
| NCT04400890 Details | 2023-02-24 Interventional | 2 | 105 | Cholecalciferol Resveratrol Vitamin D COVID-19 | Feasibility The actual rate of primary and secondary COVID-19 outcome measures were lower than expected. Therefore the study plan had inadequate number of participants and was therefore under-powered. | |||
| NCT04311710 Details | 2023-02-24 Interventional | 1 | 21 | Ipilimumab Nivolumab Tumor | Business objectives have changed - | |||
| NCT03906526 Details | 2023-02-24 Interventional | 1 | 15 | Nivolumab Carcinoma Carcinoma, Squa… | Business objectives have changed - | |||
| NCT03678506 Details | 2023-02-24 Interventional | 4 | 800 | Apixaban Thromboembolism Venous Thromboe… Anticoagulants | The study was interrupted after a planned interim analysis for the high rate of primary
outcomes (7.3%; 95% confidence interval [CI], 4.5-11.2) - | |||
| NCT03265080 Details | 2023-02-24 Interventional | 1 | [3 Refs] | 13 | Pembrolizumab Neoplasms Colon Cancer Me… Head and Neck C… Metastatic Mela… Metastatic Non-… Urothelial Carc… | Business decision - | ||
| NCT04036721 Details | 2023-02-23 Interventional | 4 | - | Prednisone Lung Diseases Lung Diseases, … Lung Neoplasms Neoplasms Pneumonia Interstitial Lu… Lung Neoplasm M… | SARS-CoV-2 cases stopped the recruitment in Organisation since July 2020 - | |||
| NCT03922620 Details | 2023-02-23 Interventional | 4 | 1 | Bupivacaine Acute Pain Anesthesia Opioid Use Pain, Acute Surgery | Additional published information on the topic since starting the study - | |||
| NCT04216693 Details | 2023-02-22 Interventional | 2 | [1 Refs] | 0 | Digoxin Fatty Liver Non-alcoholic F… Nonalcoholic St… | Administrative decision to terminate. - | ||
| NCT04177602 Details | 2023-02-22 Interventional | 1/2 | 10 | Capecitabine Trifluridine Rectal Neoplasm… Locally Advance… | Due to the amended therapy strategies for rectal cancer recently, it was decided not to
transfer the study to the phase II part, as superiority over standard chemoradiation and
transfer to a new therapy standard are increasingly unlikely. - | |||
| NCT01933815 Details | 2023-02-22 Interventional | 1/2 | - | Bevacizumab Glioblastoma Glioblastoma Mu… | Business reasons - | |||
| NCT04915144 Details | 2023-02-21 Interventional | 2 | 0 | Edotreotide lut… Carcinoid Tumor Gastrinoma Insulinoma Neuroendocrine … Gastroenteropan… Pulmonary Carci… Vipoma | Investigator decision - |